anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a compound toona ciliata domiphen bromide agentia for external use. The compound toona ciliata domiphen bromide agentia is mainly used for treating leukoplakia of vagina and has a remarkable treatment effect. The compound toona ciliata domiphen bromide agentia is prepared from toona ciliata, euscaphis japonica leaves, dendrolobium triangulare, pendulous euonymus barks or roots, denseleaf crazyweed herb, tall monkshood roots, dyetree, wild flax, schizomussaenda dehiscens, punctate ardisia herb, Chinese umbrellaleaf rhizome, quassia roots, weak equisetum, lignum rhamnellae, pogostemon auricularius, white quartz, cavalerie mosla, leontopodium leontopodioides, argyreia obtusifolia lour., polygonum lapathifolium L, sassafras tzumu, Indian melothria roots, zelkova schneideriana leaves, longleaf bastardtoadflax herb, domiphen bromide, oxytetracycline, bacitracin, dimethylacetamide, antioxidant, preservative, antisensitive agent and dispersing agent. Through reasonable compatibility of the ingredients, the functions of clearing heat and drying dampness, warming channel for arresting bleeding, eliminating cold to stop pain, dispelling wind and arresting itching and replenishing the vital essence and the blood are realized, and inflammation diminishing, bacterium resistance and allergy resistance are achieved. By the combination of Chinese medicine and western medicine, a good synergistic effect is realized. The agentia is for external use, and leukoplakia of female vagina can be effectively treated based on clinical verifications; furthermore, using is convenient, and treatment effect is remarkable.
275,183. Eichelbaum, G., and Altenburg, J. July 28, 1926, [Convention date]. Medicinal preparations. - The therapeutic efficiency of animal glands or the like, yielding hormones, is increased by subjecting the whole or comminuted glands &c. to ultra-violet rays. The substance, preferably comminuted, or reduced to a dry powder, and in some cases mixed with an inert material such as kieselguhr, is enclosed in a glass receptacle and placed before a quartz lamp, with or without the interposition of a heat filter. The vessels may be continuously or intermittently moved, or may be fitted with stirrers, so as to expose the whole contents to the rays. Substances referred to are thyroid glands, ovaries, testicles, nerve substance, gall, and pancreas. The Specification as open to inspection under Sect. 91 (3) (a) describes also the treatment of previously-made liquid extracts of the glands in water, ether, alcohol or chloroform, or of the dried extracts; the combination of the materials, before, during, or after treatment, with iodine bromine, antimony, bismuth, or arsenic, or combinations of these; the use of silica, powdered quartz, or powdered coal as inert diluents: the use of tubes or containers of quartz or Uviol glass, or of containers fitted with airtight covers having panels of such materials; the enclosure of the source of radiation within the receptacle; and the process of treating the materials whilst under vacuum or in an inert atmosphere such as carbonic acid, nitrogen, or hydrogen; and refers also to spleen and brain substance as materials which may be treated. This subject-matter does not appear in the Specification as accepted. Reference has been directed by the Comptroller to Specifications 5957/13 and 236,197.
OBJECTIVE: The weight-adjusted-waist index (WWI) serves as an innovative obesity measure, seemingly surpassing body mass index (BMI) and waist circumference (WC) in evaluating lean and fat mass. This study aimed to explore the relationship between WWI and depression in United States (US) adults.
METHODS: This population-based study investigated adults with comprehensive WWI and PHQ-9 (9-item Patient Health Questionnaire) data from the National Health and Nutrition Examination Survey (NHANES) 2005-2018. WWI was computed by dividing WC by the square root of body weight. Weighted multivariate logistic regression and smoothed curve fitting were employed to examine linear and non-linear associations. Additionally, subgroup analyses and interaction tests were conducted.
RESULTS: A total of 34,528 participants were enrolled with a prevalence of depression of 7.61 %. WWI was positively related to depression with the full adjustment [odds ratio (OR) = 1.21, 95 % confidence interval (95 % CI): 1.13-1.29]. After converting WWI to a categorical variable by quartiles (Q1-Q4), compared to Q1 the highest WWI quartile was linked to an obviously increased likelihood of depression (OR = 1.51, 95 % CI: 1.29-1.76). Subgroup analysis revealed the stability of the independent positive relationship between WWI and depression (all P for trend >0.05).
CONCLUSION: WWI levels were positively related to an increased likelihood of depression in US adults. Our findings indicated that WWI may serve as a simple anthropometric index to predict depression.
AIM: Preoperative frailty has been associated with adverse postoperative outcomes in various populations, but of its use in patients with inflammatory bowel disease (IBD) remains sparse. The present study aimed to characterize the impact of frailty, as measured by the modified frailty index (mFI), on postoperative clinical and resource utilization outcomes in patients with IBD.
METHODS: This retrospective population-based cohort study assessed patients from the National Inpatient Sample database from 1 September 2015 to 31 December 2019. Corresponding International Classification of Diseases 10th Revision Clinical Modification codes were used to identify adult patients (>18 years of age) with IBD, undergoing either small bowel resection, colectomy or proctectomy. Patient demographics and institutional data were collected for each patient to calculate the 11-point mFI. Patients were categorized as either frail or robust using a cut-off of 0.27. Primary outcomes were postoperative in-hospital morbidity and mortality, whilst secondary outcomes included system-specific morbidity, length of stay, in-hospital healthcare costs and discharge disposition. Logistic and linear regression models were used for primary and secondary outcomes.
RESULTS: Overall, 7144 patients with IBD undergoing small bowel resection, colectomy or proctectomy were identified, 337 of whom were classified as frail (i.e., mFI < 0.27). Frail patients were more likely to be women, older, have lower income and a greater number of comorbidities. After adjusting for relevant covariates, frail patients were at greater odds of in-hospital mortality (adjusted odds ratio [aOR] 5.42, 95% CI 2.31-12.77, P < 0.001), overall morbidity (aOR 1.72, 95% CI 1.30-2.28, P < 0.001), increased length of stay (adjusted mean difference 1.3 days, 95% CI 0.09-2.50, P = 0.035) and less likely to be discharged to home (aOR 0.59, 95% CI 0.45-0.77, P < 0.001) compared to their robust counterparts.
CONCLUSIONS: Frail IBD patients are at greater risk of postoperative mortality and morbidity, and reduced likelihood of discharge to home, following surgery. This has implications for clinicians designing care pathways for IBD patients following surgery.
Consumption of placebo product (carbohydrates) masked with citric, divided in two intakes. The mixture will be prepared with bicarbonate. In addition, every hour they should consume 90g of carbohydrates.
Langerhans cell histiocytosis (LCH) is a rare blood disorder. Though affecting all ages, LCH occurs more often in children, with an increased incidence in children less than 1 year of age. The disease presents in various ways, with most children suffering bony lesions, and skin rashes. In some patients, LCH affects vital organs such as liver, spleen, bone marrow, and the central nervous system. This group of patients are at significant risk of serious illness and death and are thus said to have risk-organ-positive (RO+) LCH. Current treatments for LCH consist of chemotherapy combined with other medications. However, many patients, especially those with RO+ disease, do not respond to therapy. Of the patients that do respond, many suffer progression of disease after an initial response to therapy, or recurrence of disease after completion of therapy.

The purpose of this study is to see if treatment with mirdametinib in patients with LCH or other histiocytic disorders will be better than current treatments and with fewer side effects.
Participants randomized to the waitlist group will complete all study procedures except the 3D VVRET. After the conclusion of their sessions, these participants will be offered the full 3D-VVRET treatment.
The invention deals with a method for the determination of the glomerular filtration rate after a single injection of a test dose of a corrinoid and with a method for the determination of tiny amounts of vitamin B12. This may be of importance, for example, in a wide variety of disciplines. An example of this from medicine. Clearance investigations for clinical testing of kidney function are known. Radioactive isotopes are used for this, thus exposing the human body to radioactivity. If it is possible to obtain at least equally good results in clearance investigations without exposing the human body to radioactive isotopes, this would be a great success. This is possible by detection of tiny amounts of vitamin B12 in the human body. This is achieved by saturating the B12 receptors, administering at least one test dose of vitamin B12, and subsequently determining the plasma concentration by HPLC (High Pressure Liquid Chromatography). <IMAGE>
PURPOSE:To hydrolyze proteins and polypeptides into a low-molecular weight peptide and obtain a physiologically active substance which can be orally administered, by defatting almond seeds, extracting the seeds with water and adding a proteolytic enzyme to the resultant extract solution. CONSTITUTION:Almond seeds are crushed to a suitable particle size in a mixer, etc., and an alcohol, acetone, etc., is added to defat the crushed seeds. Water is then added to the defatted almond seed powder to give an extract solution. A proteolytic enzyme, e.g. pepsine, trypsin, papain, etc., is then added to keep the above-mentioned extract solution at 2-5pH and 30-50 deg.C temperature and hydrolyze proteins and polypeptides contained therein into a low-molecular weight peptide having >=1,000-<10,000mol.wt. The reaction solution is then heated to inactivate the enzyme and concentrating under reduced pressure and drying are carried out to afford the aimed flour containing the physiologically active peptide having a reduced molecular weight in a high content.
Oxidative stress, a condition characterized by an imbalance between reactive oxygen species (ROS) production and the body's ability to detoxify them, has emerged as a pivotal factor in the pathophysiology of various diseases. Red blood cells (RBCs), essential components of the circulatory system, are particularly susceptible to oxidative damage due to their high oxygen-carrying capacity and the abundance of vulnerable biomolecules. This review comprehensively explores the intricate mechanisms underlying oxidative stress-induced damage to red blood cells and the subsequent implications for overall health and disease. We delve into the sources of ROS generation within RBCs, including metabolic processes and external factors, shedding light on the delicate redox balance that governs cellular homeostasis. The impact of oxidative stress on red blood cells extends beyond the confines of their primary physiological role, as these cells actively participate in immune responses, inflammation modulation, and nitric oxide metabolism. Consequently, understanding the implications of oxidative stress on RBCs provides valuable insights into the broader landscape of health and disease. In conclusion, this review underscores the critical role of oxidative stress in influencing red blood cell physiology and its far-reaching implications for human health. Elucidating the molecular intricacies of this relationship not only enhances our understanding of fundamental biological processes but also paves the way for the development of targeted therapeutic interventions to mitigate the adverse effects of oxidative stress on red blood cells and, by extension, on overall health.
OBJECTIVES: The purpose of this study was to examine racial disparities in opioid prescribing practices for patients presenting to the emergency department (ED) with a common chief complaint of abdominal pain.
METHODS: Treatment outcomes were compared for non-Hispanic White (NH White), non-Hispanic Black (NH Black), and Hispanic patients seen over 12 months in three emergency departments in the Minneapolis/St. Paul metropolitan area. Multivariable logistic regression models were used to estimate odds ratios (OR) with 95% confidence intervals (CI) to measure the associations between race/ethnicity and outcomes of opioid administration during ED visits and discharge opioid prescriptions.
RESULTS: A total of 7309 encounters were included in the analysis. NH Black (n = 1988) and Hispanic patients (n = 602) were more likely than NH White patients (n = 4179) to be in the 18-39 age group (p < 0. 001). NH Black patients were more likely to report public insurance than NH White or Hispanic patients (p < 0.001). After adjusting for confounders, patients who identified as NH Black (OR: 0.64, 95% CI: 0.56-0.74) or Hispanic (OR: 0.78, 95% CI: 0.61-0.98) were less likely to be given opioids during their ED encounter when compared to NH White patients. Similarly, NH Black patients (OR: 0.62, 95% CI: 0.52-0.75) and Hispanic patients (OR: 0.66, 95% CI: 0.49-0.88) were less likely to receive a discharge opioid prescription.
CONCLUSIONS: These results confirm that racial disparities exist in the ED opioid administration within the department as well as at discharge. Future studies should continue to examine systemic racism as well as interventions to alleviate these health inequities.
Single oral dose of MK-8510 administered at dose level 1 (≤1800 mg) following a 10-hour fast. Dose level 1 shall not exceed 1800 mg.
Low dose level(3µg) for GBP560-A in stage 1. Participants will receive 2 doses of one of the test vaccines at 4-week intervals, respectively.
BACKGROUND: Purulent pericarditis (PP)- a purulent infection involving the pericardial space-requires a high index of suspicion for diagnosis as it often lacks characteristic signs of pericarditis and carries a mortality rate as high as 40% even with treatment. Common risk factors include immunosuppression, diabetes mellitus, thoracic surgery, malignancy, and uremia. Most reported cases of PP occur in individuals with predisposing risk factors, such as immunosuppression, and result from more commonly observed preceding infections, such as pneumonia, osteomyelitis, and meningitis. We report a case of PP due to asymptomatic bacteriuria in a previously immunocompetent individual on a short course of high-dose steroids.
CASE PRESENTATION: An 81-year-old male presented for severe epigastric pain that worsened with inspiration. He had been on high-dose prednisone for presumed inflammatory hip pain. History was notable for urinary retention requiring intermittent self-catheterization and asymptomatic bacteriuria and urinary tract infections due to methicillin-sensitive Staphylococcus aureus (MSSA). During the index admission he was found to have a moderate pericardial effusion. Pericardial fluid cultures grew MSSA that had an identical antibiogram to that of the urine cultures. A diagnosis of purulent pericarditis was made.
CONCLUSION: PP requires a high index of suspicion, especially in hosts with atypical risk factors. This is the second case of PP occurring as a result of asymptomatic MSSA bacteriuria. Through reporting this case we hope to highlight the importance of early recognition of PP and the clinical implications of asymptomatic MSSA bacteriuria in the setting of urinary instrumentation and steroid use.
The invention discloses a pericarp ferment mask and a preparation method thereof. The pericarp ferment mask comprises a mask cloth and a mask liquid. The mask cloth is immersed in the mask liquid. The mask liquid comprises, by weight, 4-6 parts of a pericarp ferment stock solution, 4-6 parts of mucopolysaccharide, 3-5 parts of glycerin, 3-4 parts of an emulsifier, 2-4 parts of arbutin, 2-4 parts of mushroom glucan, 1-3 parts of hyaluronic acid, 1-3 parts of collagen peptide powder, 1-2 parts of vitamin E, 4-6 parts of propylene glycol, 1-1.5 parts of a thickening agent, 0.4-0.8 parts of dipotassium glycyrrhizinate, 0.1-0.3 parts of an antiseptic, 0.05 parts of essence and 50-70 parts of deionized water. The preparation method creatively uses a pericarp ferment in cosmetics. The pericarp ferment is rich in naringin and a plurality of vitamins. Through natural fermentation of pericarp, active ingredients of the pericarp are fully dissolved out and can be absorbed easily by skin.
The invention discloses a medicine for treating rhinopathy. The medicine comprises the following active pharmaceutical ingredients in parts by weight: 12-17 parts of Danshen root, 8-13 parts of cowherb seed, 10-15 parts of Szechuan lovage rhizome, 12-17 parts of small centipeda herb, 12-17 parts of dahurian angelica root, 12-17 parts of flower bud of lily magnolia, 8-13 parts of baikal skullcap root, 8-13 parts of Siberian cocklour fruit, 1-5 parts of manchurian wildginger herb and 1-3 parts of borneol. The medicine is obtained by weighing the active pharmaceutical ingredients according to the parts by weight, washing, drying and sterilizing, soaking and decocting the active pharmaceutical ingredients, filtering the decoction, cooling the filtrate and re-sterilizing the filtrate. The medicine provided by the invention has the characteristics of quickness in effect taking, good curative effects and small side effects. The medicine is clinically used by totally 647 patients and the average cure rate is 92.8%. The medicine is convenient and fast to use.
Peptides having four to fourteen residues are disclosed that possess biological activity. These peptides constitute short fragments of the peptide HB-107 (SEQ ID NO:1), which itself is a fragment of the antimicrobial protein cecropin B, and exhibit cell stimulatory, migratory and anti-inflammatory properties. As keratinocytes are especially sensitive to these effects, the disclosed peptides comprise a useful agent for the medical treatment of injury to the skin, such as from diabetic ulcers. The peptides also are effective in preventing and reversing skin surface damage resulting from various environmental insults. Importantly, the therapeutic effects of the peptides manifest at concentrations equal to or greater than those of peptide HB-107, and thus represent a less expensive, more versatile means for developing effective therapies. Methods for the production and use of these peptides are also disclosed.
Domestic dogs are currently recognized as being infected by 25 different canine papillomavirus (CPV) types classified into three genera. A short sequence from a novel CPV type was amplified, along with CPV1, from a papilloma (wart) from the mouth of a dog. The entire 7499 bp genome was amplified, and CPV26 contained putative coding regions that were predicted to produce four early proteins and two late ones. The ORF L1 showed less than 62% similarity for all previously sequenced CPV types but over 69% similarity to multiple Omegapapillomavirus types from a variety of Caniform species including the giant panda, Weddel seal, and polar bear. Phylogenetic analysis confirmed CPV26 clusters within the Omegapapillomavirus genus. Specific primers were used to investigate the presence of CPV26 DNA within a series of 37 canine proliferative lesions. CPV26 DNA was amplified from one lesion, a cutaneous papilloma that also contained CPV6. This is the first time a PV type within the Omegapapillomavirus genus has been detected in a non-domestic species and this provides evidence that the omegapapillomaviruses infected a common ancestor of, and then co-evolved with, the Caniform species. Whether CPV26 causes disease is uncertain, but the absence of an E7 protein may suggest low pathogenicity.
Heart transplant patients who fulfill selection criteria will undergo baseline clinical evaluation and data collection. Participants will be randomized to either placebo, aspirin or clopidogrel to be taken daily for the duration of the study. Patients will undergo invasive coronary studies (angiography, optical coherence tomography and intracoronary flow) and platelet function testing at 2 and 12 months post heart transplant. In addition, angiography will be performed at 24 months post heart transplant and thereafter according to institutional protocol. The primary analysis will determine the feasibility of conducting a large multicenter randomized placebo controlled trial by assessing recruitment rates, event rates, treatment crossovers and loss to follow-up. Secondary analyses will include assessing the effect of antiplatelet treatment on angiographic CAV, coronary intimal disease on optical coherence tomography, coronary macrovascular and microvascular function by intracoronary flow measures, and platelet function.
Patients receive sargramostim SC daily on days 1 and 2 and wild-type reovirus IV over 60 minutes on days 3-5. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
The relatively slow elimination of fluoxetine (elimination half-life of 1 to 3 days after acute administration and 4 to 6 days after chronic administration) and its active metabolite, norfluoxetine (elimination half-life of 4 to 16 days after acute and chronic administration), leads to significant accumulation of these active species in chronic use and delayed attainment of steady-state, even when a fixed dose is used [see Warnings and Precautions (5.12)]. After 30 days of dosing at 40 mg/day, plasma concentrations of fluoxetine in the range of 91 to 302 ng/mL and norfluoxetine in the range of 72 to 258 ng/mL have been observed. Plasma concentrations of fluoxetine were higher than those predicted by single-dose studies, because fluoxetine’s metabolism is not proportional to dose. Norfluoxetine, however, appears to have linear pharmacokinetics. Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days. Steady-state levels after prolonged dosing are similar to levels seen at 4 to 5 weeks. 

The long elimination half-lives of fluoxetine and norfluoxetine assure that, even when dosing is stopped, active drug substance will persist in the body for weeks (primarily depending on individual patient characteristics, previous dosing regimen and length of previous therapy at discontinuation). This is of potential consequence when drug discontinuation is required or when drugs are prescribed that might interact with fluoxetine and norfluoxetine following the discontinuation of fluoxetine.